Peptide Therapy + Hormone Optimisation
Documented synergy between Peptide Therapy and Hormone Optimisation. Canonical combination in literature · see protocol and evidence.
View comparison →Precise molecular signals to repair and optimise the body
Definition and how it works: Therapeutic peptides are short amino acid chains (2–50 amino acids) that act as molecular signals in the body, activating specific receptors with high selectivity and safety. Unlike hormones, peptides act in a more localised and transient manner. The most commonly used in longevity medicine are BPC-157 (tissue repair), TB-500 (recovery), GHK-Cu (skin and regeneration), Epithalon (telomeres) and growth hormone secretagogues (CJC-1295, Ipamorelin).
Therapeutic peptides are short amino acid chains (2–50 amino acids) that act as molecular signals in the body, activating specific receptors with high selectivity and safety. Unlike hormones, peptides act in a more localised and transient manner. The most commonly used in longevity medicine are BPC-157 (tissue repair), TB-500 (recovery), GHK-Cu (skin and regeneration), Epithalon (telomeres) and growth hormone secretagogues (CJC-1295, Ipamorelin).
Origin and history
Bioactive peptides were first identified in the 1950s–60s. Dr Vladimir Khavinson at the Saint Petersburg Institute of Gerontology developed bioregulatory peptides in the 1970s. Their clinical use in longevity has gained global popularity since 2015.
1. Assessment and selection Review of goals, hormonal blood work and medical history. Selection of specific peptides.
2. Medical prescription Prescription by an authorised physician. Sourced from a compounding pharmacy or clinic.
3. Self-injection training Subcutaneous technique in abdomen or thigh. Insulin syringes (31G). Injection site rotation.
4. Administration protocol Frequency varies by peptide: daily (BPC-157), 2–3 weeks (Epithalon), 5-on/2-off (GH secretagogues).
5. Follow-up blood work Control blood panel at 8–12 weeks. Dose adjustment based on response.
| Equipment | Brand / Model | Technical detail |
|---|---|---|
| 31G insulin syringes | BD Micro-Fine / Terumo | 0.3 ml / 31G × 6 mm. For subcutaneous injection with minimal discomfort. |
| Lyophilised peptide vial | Compounding pharmacy / Clinique peptides | Reconstitution with bacteriostatic water. Refrigerated storage (2–8 °C). |
Clinics on LongevityMap declare their exact equipment for objective scoring.
Precise molecular signals to repair and optimise the body
€80–300 per monthly protocol
Daily or every 2–3 days (subcutaneous or intranasal)
Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.
Documented synergy between Peptide Therapy and Hormone Optimisation. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Peptide Therapy and NAD+ IV Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Peptide Therapy and Stem Cell Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →We are collecting signed consents under GDPR Art. 9.2.a. First verified testimonials will appear once the first real clinics are onboarded (Q4 2026).
BPC-157 has been shown in multiple animal studies to accelerate the healing of tendons, ligaments and gastrointestinal tissue via the VEGF pathway and nitric oxide synthesis. Epithalon (a pineal gland tetrapeptide) has demonstrated telomere lengthening and reduced mortality in animal models in studies at the Khavinson Institute. GH secretagogues stimulate the natural pulsatile release of growth hormone.
Frontiers in Aging 2026: review of 9 peptides for healthy aging — metabolic restoration (tirzepatide), telomere (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), GH modulation (CJC-1295, ipamorelin), sexual function (bremelanotide). FDA-approved with robust safety; non-approved show promising preclinical but limited human evidence.
Sports Medicine 2026: review of approved (tesamorelin) and unapproved (BPC-157, GHK-Cu, MOTS-C, TB-500) peptides for musculoskeletal injuries and athletic performance. Many unapproved peptides show favourable tissue repair in animal models, but rigorous human safety data are scarce. Potential for serious harm.
2026 BPC-157 review: shows reparative and anti-inflammatory properties in preclinical (angiogenesis, collagen synthesis, NO modulation), pain modulation via peripheral and dopaminergic mechanisms. Human research limited to small pilot studies. Controlled trials needed before clinical translation.
2026 SR (growth factors + BPC-157 in musculoskeletal and junctional injuries): BPC-157 systemic or local, without scaffolds, demonstrated consistent efficacy in tendon, ligament, muscle and osteotendinous/myotendinous junctions in rat studies. Human clinical validation pending.
Last bibliographic review: 2026-03-28.
Some peptides are registered as medicines (such as BPC-157 in certain countries). Others are prescribed under compassionate use or within studies. It is essential to obtain them through a supervised medical clinic, not from unregulated sources.
Epithalon (Epitalon) is the most researched for direct longevity, with studies showing telomere lengthening. For recovery, BPC-157 is the most requested. For hormonal optimisation, GH secretagogues (CJC-1295 + Ipamorelin) are the most widely used.
Peptide protocols are usually initiated at a clinic under medical supervision. Many patients learn to self-administer subcutaneous injections at home once the protocol is established.
Tell us your goal and budget. We cross-reference 500+ clinical parameters and generate 3 personalised plans with Peptide Therapy.
Generate My Protocol for freeLongevityMap content is for informational and educational purposes only. It does not constitute personalised medical advice. Always consult a healthcare professional before starting any treatment. Our team · Methodology